[ad_1]
Head of the Department of Pediatric Infectious Diseases at Hacettepe University School of Medicine. Dr. Mehmet Ceyhan on Turkey’s future chorus vaccine from China, said the inactivated vaccine, said it should increase screening for this vaccine.
“REAL EFFICIENCY MUST BE EVALUATED BY SCREENING TESTS”
Head of the Department of Pediatric Infectious Diseases at Hacettepe University School of Medicine. Dr. Mehmet Ceyhan, it was very important to share information about the vaccine with the choir that comes to Turkey from China. Noting that the vaccine from China is inactive, Ceyhan said these vaccines are easily prepared, but there are safety risks. Stating that diseases such as polio and hepatitis A are also vaccinated with this method, Prof. Dr. Ceyhan, “When using the vaccine, we must increase the screening tests and then evaluate the actual effectiveness.”
WHAT SHOULD WE TAKE CARE OF FROM INACTIVE VACCINES?
Prof. Dr. Mehmet Ceyhan used the following statements in his post on his Twitter account:
“The pandemic is progressing widely. We must use the Kovid-19 vaccine as soon as possible. Even the least effective vaccine is much better than the consequences of the disease. It seems that we will use inactivated vaccines. Inactivated vaccines are an ancient method of vaccine development. Many inactivated vaccines Although the vaccine has been replaced by higher technology vaccines, we still use inactivated vaccines for polio and hepatitis A.
There are points we must be careful about in the vaccines that we import and develop by Aykut Hodja. Why were inactivated (killed) vaccines, the fastest and simplest method in the 2003 SARS epidemic, not tested in humans? While a large number of vector and DNA vaccines for SARS virus, the ancestor of the virus that caused Kovid in 2003, were tested in humans, the inactivated vaccine was not tested. Why;
1) Inactivated vaccines are easily and quickly prepared, but they present a safety risk and require the most attention with live vaccines in terms of their biological control. Active virus controls must be performed on cultures. Animal experiments may not completely eliminate the risk.
2) There is a risk of contamination during its preparation.
3) The use of the whole virus as an antigen can sometimes lead to the development of antibodies that facilitate the entry of the virus into the cell.
4) Infection prevention type (neutralized) antibodies may be lower when all virus spike proteins are administered than a specific part. Therefore, when using the vaccine, we must increase the screening tests and then evaluate the real efficacy. “
[ad_2]
